AprilBio Co.,Ltd.
KOSDAQ-listed biotech out-licensing SAFA-platform long-acting antibody candidates to global pharma partners such as Lundbeck and Evommune.
As of 2026-10-10, AprilBio Co.,Ltd. has 10 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2013 and listed on KOSDAQ in 2022, AprilBio is an antibody therapeutics R&D company. It develops antibody drugs, bispecific antibodies, long-acting biologics, and ADC-applied antibodies using its human antibody library technology (HuDVFab library) and its SAFA (anti-Serum Albumin Fab-Associated technology) half-life extension platform. It has signed five out-licensing deals to date, including a $448 million deal with Denmark's H. Lundbeck A/S in October 2021 and a $475 million deal with Evommune, Inc. of the U.S. in June 2024.
R&D and key agreements
Source: DART corporate disclosureSAFA(anti-Serum Albumin Fab-Associated technology) · 자가면역질환·염증질환·암·희귀질환 · 플랫폼 기술 · Half-life extension platform based on serum-albumin-binding Fab antibody SL335
HuDVFab library · 플랫폼 기술 · Human antibody library technology for candidate discovery
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis.
Cell reports. Medicine · 2025-04 · Kim DH, Choi G, Song EB 외 14
- Development of a Long-Acting Follicle-Stimulating Hormone Using Serum Albumin Fab-Associated Technology for Female Infertility.
Endocrinology and metabolism (Seoul, Korea) · 2025-02 · Kim D, Cho YH, Kang MJ 외 11
- Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation.
Cytokine · 2023-12 · Jang YS, Lee K, Park M 외 10
- Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023-11 · Kim DH, Lee KJ, Park J 외 7
- Long-acting recombinant human follicle-stimulating hormone (SAFA-FSH) enhances spermatogenesis.
Frontiers in endocrinology · 2023-01 · Kim D, Lee S, Cho YH 외 10
- APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin.
Veterinary immunology and immunopathology · 2021-10 · Chi HJ, Park M, Han JK 외 4
- Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.
Biochemical and biophysical research communications · 2020-06 · Cho SY, Han J, Cha SH 외 1
- Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
Immunology letters · 2019-03 · Ji SI, Park JH, You HG 외 3
- Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule.
Immunology letters · 2017-04 · Kang HJ, Kim HJ, Jung MS 외 2
- Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life.
Immunology letters · 2016-01 · Kang HJ, Kim HJ, Cha SH
Patents
KIPRIS · applicant-matchedCN · Published · 2024-11 · Application 202480045083.8
Published · 2024-11 · Application 1020267020254
PCT · Published · 2024-11 · Application PCT/EP2024/083686
US · Published · 2024-09 · Application 18895157
PCT · Published · 2024-06 · Application PCT/IB2024/055506
CN · Published · 2023-10 · Application 202380087105.2
US · Published · 2023-10 · Application 19120348
EP · Published · 2023-10 · Application 23879315.2
PCT · Published · 2023-10 · Application PCT/IB2023/060573
CN · Published · 2023-10 · Application 202380082890.2
Show 36 more patents
US · Published · 2023-10 · Application 19118074
EP · Published · 2023-10 · Application 23874414.8
PCT · Published · 2023-10 · Application PCT/IB2023/059986
US · Registered · 2023-01 · Application 18151227
Published · 2022-10 · Application 1020220135135
Published · 2022-10 · Application 1020220126516
CN · Published · 2021-09 · Application 202180079645.7
Published · 2021-09 · Application 1020237014869
US · Published · 2021-09 · Application 18246423
EP · Published · 2021-09 · Application 21874697.2
PCT · Published · 2021-09 · Application PCT/IB2021/058964
CN · Published · 2021-04 · Application 202180027530.3
US · Published · 2021-04 · Application 17917490
US · Registered · 2021-04 · Application 17917513
EP · Published · 2021-04 · Application 21783964.6
EP · Published · 2021-04 · Application 21784423.2
PCT · Published · 2021-04 · Application PCT/IB2021/052969
PCT · Published · 2021-04 · Application PCT/IB2021/052934
CN · Published · 2021-01 · Application 202180023540.X
Published · 2021-01 · Application 1020227029379
US · Published · 2021-01 · Application 17759313
EP · Published · 2021-01 · Application 21744981.8
PCT · Published · 2021-01 · Application PCT/IB2021/050519
Published · 2020-11 · Application 1020200144595
Withdrawn · 2020-09 · Application 1020200127395
US · Published · 2020-05 · Application 16878255
Registered · 2020-04 · Application 1020200043606
Withdrawn · 2020-01 · Application 1020200009565
US · Registered · 2017-09 · Application 15717528
US · Registered · 2016-02 · Application 15056299
Rejected · 2015-09 · Application 1020150136164
Registered · 2014-09 · Application 1020140115673
CN · Published · 2014-08 · Application 201480056265.1
EP · Registered · 2014-08 · Application 14839630.2
EP · Published · 2014-08 · Application 19192902.5
PCT · Published · 2014-08 · Application PCT/KR2014/008106
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive6
- OpenAIOAI-SearchBot24
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for AprilBio Co.,Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition